AstraZeneca Pharma India Limited — Important, 11-02-2025: General Updates

AstraZeneca Pharma India Limited has received a warning letter from BSE Limited regarding a violation of the quorum requirements for its Audit Committee meeting held on May 27, 2024. Specifically, only one Independent Director attended, which does not meet the minimum requirements stipulated by SEBI regulations.

While the letter emphasizes the seriousness of the compliance issue, it is noted that there is no immediate financial or operational impact on the company. AstraZeneca is advised to ensure adherence to SEBI regulations moving forward and to present this warning and corrective actions to its Board of Directors. Investors should monitor the company's governance practices closely, as any future compliance issues could have implications for operational integrity and market perception.